In these instances, administering NAMPT inhibitors in combination with NA is postulated to help many healthy, NAPRT-proficient tissues, but not NAPRT-deficient cancer cells in avoiding the consequences of NAMPT obstruction. The gene discussed is NAPRT; the disease is cancer.